Immunic's future growth prospects depend heavily on the successful clinical development and eventual commercialization of its lead proprietary asset, vidofludimus calcium, currently advancing through late-stage clinical trials like the Phase 3 ENSURE program for relapsing multiple sclerosis. Positive clinical readouts, successful regulatory approvals, and potential expansion into additional autoimmune indications could unlock massive market opportunities for its oral therapy portfolio. However, like all pre-revenue biopharmaceutical firms, future success remains tied to clinical efficacy, regulatory clearance, and efficient capital management.